Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, briefly discusses the promise of CD30-targeting CAR-T therapies for patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.